(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Revlimid has arguably been the single biggest growth driver for Dr Reddy's in recent years, fueling record-high US sales last ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1 (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Revlimid is already approved to treat multiple myeloma and the blood disorder myelodysplastic syndromes. In its first quarter, Revlimid's sales totalled approximately US $1 billion.

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Indian shares closed lower on Friday after a choppy session. Markets gave up early gains as concerns about slowing earnings growth ...

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...